HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry

被引:10
|
作者
Cordova, Claudio [1 ,2 ]
Munoz, Roberto [2 ,3 ]
Olivares, Rodrigo [3 ,4 ]
Minonzio, Jean-Gabriel [2 ,3 ,4 ,5 ]
Lozano, Carlo [6 ]
Gonzalez, Paulina [6 ,7 ]
Marchant, Ivanny [8 ]
Gonzalez-Arriagada, Wilfredo [9 ,10 ]
Olivero, Pablo [1 ,2 ]
机构
[1] Univ Valparaiso, Fac Med, Cell Funct & Struct Lab EFC Lab, 2664 Hontaneda, Valparaiso 2341386, Chile
[2] Univ Valparaiso, Fac Engn, PhD Program Hlth Sci & Engn, Valparaiso 2362735, Chile
[3] Univ Valparaiso, Fac Engn, Sch Informat Engn, Valparaiso 2362735, Chile
[4] Univ Valparaiso, Fac Engn, Ctr Res & Dev Hlth Engn, Valparaiso 2362735, Chile
[5] Univ Valparaiso, Fac Engn, Millennium Inst Intelligent Healthcare iHEALTH, Valparaiso 2362735, Chile
[6] Carlos Van Buren Hosp, Pathol Anat Serv, Valparaiso 2340105, Chile
[7] Andres Bello Natl Univ UNAB, Sch Med Technol, Vina Del Mar 2520000, Chile
[8] Univ Valparaiso, Fac Med, Med Modeling Lab, Valparaiso 2362735, Chile
[9] Univ Los Andes, Fac Dent, Santiago 7620086, Chile
[10] Univ Los Andes, Biomed Res & Innovat Ctr CIIB, Santiago 7620086, Chile
关键词
breast cancer; HER2; IHC; ML; SHAP; RECEPTOR; EXPRESSION; WOMEN; CONSENSUS;
D O I
10.3892/ol.2022.13630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter-observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. Implementing automatic algorithms to classify IHC biomarkers is crucial for typifying the tumor and deciding on therapy for each patient with better performance. The present study aims to demonstrate that, using an explainable Machine Learning (ML) model for the classification of HER2 photomicrographs, it is possible to determine criteria to improve the value of IHC analysis. We trained a logistic regression-based supervised ML model with 393 IHC microscopy images from 131 patients, to discriminate between upregulated and normal expression of the HER2 protein. Pathologists' diagnoses (IHC only) vs. the final diagnosis complemented with FISH (IHC + FISH) were used as training outputs. Basic performance metrics and receiver operating characteristic curve analysis were used together with an explainability algorithm based on Shapley Additive exPlanations (SHAP) values to understand training differences. The model could discriminate amplified IHC from normal expression with better performance when the training output was the IHC + FISH final diagnosis (IHC vs. IHC + FISH: area under the curve, 0.94 vs. 0.81). This may be explained by the increased analytical impact of the membrane distribution criteria over the global intensity of the signal, according to SHAP value interpretation. The classification model improved its performance when the training input was the final diagnosis, downplaying the weighting of the intensity of the IHC signal, suggesting that to improve pathological diagnosis before FISH consultation, it is necessary to emphasize subcellular patterns of staining.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The effects of bufadienolides on HER2 overexpressing breast cancer cells
    Wang, Tianjiao
    Mu, Lin
    Jin, Haifeng
    Zhang, Peng
    Wang, Yueyue
    Ma, Xiaochi
    Pan, Jinjin
    Miao, Jian
    Yuan, Yuhui
    TUMOR BIOLOGY, 2016, 37 (06) : 7155 - 7163
  • [42] The development of machine learning algorithms for decisionmaking support to help evaluate HER2/new-status in breast cancer diagnostics
    Semenova, A.
    Galkin, V.
    Andreeva, Y.
    Vishnevskaya, Y.
    Savelov, N.
    Shatalov, V.
    Andryukhina, Y.
    Kondratenko, I.
    Voronkina, D.
    Pirogova, V.
    Polyvanov, L.
    Artemieva, A.
    VIRCHOWS ARCHIV, 2024, 485 : S397 - S397
  • [43] Prediction of HER2 expression in breast cancer by combining PET/CT radiomic analysis and machine learning
    Chen, Yiwen
    Wang, Ziyang
    Yin, Guotao
    Sui, Chunxiao
    Liu, Zifan
    Li, Xiaofeng
    Chen, Wei
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (02) : 172 - 182
  • [44] Prediction of HER2 expression in breast cancer by combining PET/CT radiomic analysis and machine learning
    Yiwen Chen
    Ziyang Wang
    Guotao Yin
    Chunxiao Sui
    Zifan Liu
    Xiaofeng Li
    Wei Chen
    Annals of Nuclear Medicine, 2022, 36 : 172 - 182
  • [45] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [46] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [47] Emerging new treatments in HER2 positive breast cancer
    Piccart, M.
    BREAST, 2023, 68 : S9 - S10
  • [48] Applying the New Guidelines of HER2 Testing in Breast Cancer
    Zhang, Huina
    Moisini, Ioana
    Ajabnoor, Rana M.
    Turner, Bradley M.
    Hicks, David G.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (05)
  • [49] Applying the New Guidelines of HER2 Testing in Breast Cancer
    Huina Zhang
    Ioana Moisini
    Rana M. Ajabnoor
    Bradley M. Turner
    David G. Hicks
    Current Oncology Reports, 2020, 22
  • [50] Testing for HER2 in breast cancer
    Lewis, F
    Jackson, P
    Lane, S
    Coast, G
    Hanby, AM
    HISTOPATHOLOGY, 2004, 45 (03) : 207 - 217